Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 30, 2025European Heart Journal - Case ReportsOpen Access

Cardiac contractility modulation as a novel therapeutic approach in transthyretin amyloid cardiomyopathy to improve eligibility to stabilizer therapy: a case report

View Full Paper
Ask AI
Bookmark
Share

Authors

AEArancha Díaz ExpósitoACAlejandro I. Pérez CabezaPMPaloma Márquez-Camas

Discussion

Loading...

Member takes

Implication

Case report reveals cardiac contractility modulation improves ventricular function in transthyretin amyloidosis, indicating potential access to therapy.

Key Points

  • Ventricular function improved following cardiac contractility modulation in a 76-year-old with ATTR-CM and reduced left ventricular ejection fraction.
  • Implantation of a cardiac contractility modulation device led to an increase in left ventricular ejection fraction from 43% to 54% over 11 months, enabling Tafamidis initiation.
  • Case report highlights potential benefits of contractility modulation in addressing systolic dysfunction in amyloidosis.
  • Findings suggest exploring cardiac contractility modulation as a therapeutic option in patients with transthyretin amyloidosis.

Cite This Study

Expósito et al. (2025) studied this question.

synapsesocial.com/papers/692b9da01d383f2b2a37a34ahttps://doi.org/10.1093/ehjcr/ytaf608
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiac Amyloidosis Due to Transthyretin Protein2024 · 249 citations
  2. 2Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy2018 · 2,861 citations